PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis
Authors:
- 30 September 2015
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (3) , 3059-3069
Abstract
Epithelial ovarian cancer (EOC) is the most lethal of the gynecologic malignancies, mainly due to the advanced stage at diagnosis and development of cisplatin resistance. The sensitivity of tumor cells to cisplatin is frequently affected by defect in DNA mismatch repair (MMR), which repairs mispaired DNA sequences and regulates DNA-damage-induced apoptosis. However, the role of postmeiotic segregation increased 2 (PMS2), a member of MMR protein family, in cisplatin resistance remains elusive. In the present study, we demonstrated the frequent deficiency of PMS2 and phosphorylation of Akt in EOC cell lines and tissues. Results of complex immunoprecipitation (co-IP) and protein stability assay indicated that activated Akt could directly bind to PMS2 and cause degradation of PMS2 in EOC cells. In addition, functional experiments revealed that PMS2 was required for cisplatin-induced apoptosis and cell cycle arrest in G2/M phase. These findings provide a novel insight into molecular mechanisms linking MMR with chemoresistance and suggest that stabilization of PMS2 expression may be useful in overcoming the cisplatin resistance in EOC.Keywords
This publication has 32 references indexed in Scilit:
- Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicityNucleic Acids Research, 2013
- Down-Regulation of DNA Mismatch Repair Enhances Initiation and Growth of Neuroblastoma and Brain Tumour Multicellular SpheroidsPLOS ONE, 2011
- Gene Expression Profile and Mutational Analysis of DNA Mismatch Repair Genes in Carcinoma Prostate in Indian PopulationOMICS: A Journal of Integrative Biology, 2011
- Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3β is implicated in the treatment of cervical carcinomaBMC Cancer, 2010
- How do real tumors become resistant to cisplatin?Cell Cycle, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- The multifaceted mismatch-repair systemNature Reviews Molecular Cell Biology, 2006
- Lynch Syndrome GenesFamilial Cancer, 2005
- Development of resistance to a trinuclear platinum complex in ovarian carcinoma cellsInternational Journal of Cancer, 2003